- Develop a model for sustainable supply and costing
- Model the impact of different use cases and scenarios
- Pilot antihelmintic resistance surveillance based on genetic epidemiology
- ## Objetivos y logros de los proyectos STOP previos (en background)
- Qualification at EMA for art. 58
- Safety of IVM up to 600μg/kg alone and in coformulation with albendazole
- Demonstrated efficacy agrainst T. trichiura in a pivotal trial in Sub-Saharan Africa
- Timeline y milestones (cuáles se han cumplido?)
- ## Timeline y milestones (cuáles se han cumplido?)
- __Proposed safety and effectiveness study__
- *Primary objective*: To evaluate and compare safety of a [[FDC]] against [[Albendazole]] alone via [[MDA]] in two study areas in Kenya and [[Ghana]].
- *Secondary objectives*:
@ -35,8 +31,12 @@
- *Countries*: [[Ghana]] and [[Kenya]]
- *Epidemiologic conditions of the sites*: Ongoing [[STH]] deworming activities
-
- ## FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016)
- Main results of previous STOP projects: ALIVE pivotal Trial
- ## Objetivos y logros de los proyectos STOP previos (en background)
- Qualification at EMA for art. 58
- Safety of IVM up to 600μg/kg alone and in coformulation with albendazole
- Demonstrated efficacy agrainst T. trichiura in a pivotal trial in Sub-Saharan Africa
- ## Otros facts
- FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016)
- Investigadores principales de cada uno de los partners
- Ideas generales importantes
- Dosing strategies for Ivermectine are being revisited
Borja Robert
11 months ago